Floatz logo

5-azacytidine

Refractory

Ruijin HospitalPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Refractory cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
UNC Lineberger Comprehensive Cancer Center
Phase 2B
Cyclophosphamide
The Second Hospital of Shandong University
Phase 2B
Epirubicin
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Pomalidomide
UNC Lineberger Comprehensive Cancer Center
Phase 2CCC
Isatuximab
UNC Lineberger Comprehensive Cancer Center
Phase 2CCC

View all 33 →

Same molecule, other indications

5-azacytidine is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BB
Indicative ·
70 / 100
View asset →
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →